© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Author | George R. Blumenshein, MD
Articles
Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors
December 03, 2000
ByRitsuko Komaki, MD|Nora A. Janjan, MD|Jaffer A. Ajani, MD|Patrick M. Lynch, MD|Jackie S. Fairweather, RN|Isaac Raijman, MD|George R. Blumenshein, MD|Linus Ho, MD, PhD|Peter W. T. Pisters, MD|Barry W. Feig, MD|Garrett L. Walsh, MD|Richard Pazdur, MDIrinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly